Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes
Real-world reviews highlight Ros ease of use, especially when it comes to communication, medication access, and provider responsiveness
What 2026 has produced is a broader and more differentiated treatment landscape in which the right option depends on a patients weight loss goals, comorbidities, lifestyle constraints, and capacity for adherence to daily or weekly dosing protocols
An accurate definition of WR or IWL and monitoring basal or post-prandial GLP-1 levels with a standardized and easily accessible test may be a way to select eligible patients for adjunctive GLP-1-RA therapy post MBS
For patients whose concern is surface texture, fine lines, and overall skin quality rather than structural laxity, SkinPen microneedling stimulates collagen production in the upper dermis through controlled micro-injuries
When discussing weight loss medicines, it is helpful to ask your GP or specialist about: Currently licensed and NICE-approved options available to you on the NHS or privately Eligibility criteria for specific treatments and what monitoring would be required Realistic expectations regarding weight loss outcomes, timescales, and the importance of lifestyle changes alongside medication Potential side effects , including gastrointestinal symptoms commonly associated with GLP-1 receptor agonists, and how these are managed If you experience any suspected side effects from a weight management medicine, you can report these directly to the MHRA via the Yellow Card Scheme (available at yellowcard.mhra.gov.uk)
